why choose us

First received: March 30, 2023

Clinical Trial: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Leptomeningeal Disease

Study Type: INTERVENTIONAL


Official Title: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast

Brief Summary: The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease

Read more